Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series C | Alive

Total Raised


Last Raised

$62M | 4 yrs ago

About Amphivena Therapeutics

Amphivena Therapeutics, in collaboration with Affimed, develops bispecific TandAbs for hematologic malignancies. TandAbs are tetravalent bispecific antibody formats that have two binding sites for each antigen. Tandems are tetravalent bispecific antibody formats (~100kD) that recruit tumor destroying T cells to tumor cells. By harnessing the immune system, Amphivena's programs offer potential improvements in efficacy for patients with life-threatening hematologic cancers.

Amphivena Therapeutics Headquarters Location

611 Gateway Blvd Suite 810

South San Francisco, California, 9408,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Amphivena Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Amphivena Therapeutics is included in 3 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Amphivena Therapeutics Patents

Amphivena Therapeutics has filed 9 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Monoclonal antibodies
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Transcription factors


Application Date


Grant Date



Related Topics

Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Transcription factors



Latest Amphivena Therapeutics News

Amphivena Presents New Monotherapy and First Combination Therapy Clinical Data in Solid Tumor Patients

Jun 4, 2021

Investigational Drug Candidate AMV564 Demonstrates Safety with Evidence of Anti-tumor T cell Expansion and One Complete Response, Multiple Mixed Responses and Durable Disease Stabilization in Solid Tumor Patients No Cytokine Release Syndrome (CRS) reported in patients treated with subcutaneously administered AMV564 alone and in combination with Pembrolizumab at doses selected for expansion cohorts Monotherapy dose escalation demonstrates safety and efficacy of subcutaneously (sc) administered AMV564, including a RECIST complete response (CR) AMV564 shown to deplete immunosuppressive MDSC, significantly activate effector CD8+ cells and Th1 T cells, and promote expansion of anti-tumor T cells Phase 1 data support dose and schedule of AMV 564 for expansion cohorts in selected solid tumor indications June 04, 2021 10:00 AM Eastern Daylight Time SOUTH SAN FRANCISCO--( BUSINESS WIRE )--Amphivena Therapeutics, a clinical-stage oncology company focused on developing immune-therapeutics that restore anti-cancer immunity to patients, today reported a favorable safety profile for AMV564 and clinical responses including a CR in patients with advanced relapsed or refractory solid tumors. The poster presentation at the 2021 virtual American Society of Clinical Oncology (ASCO) Annual Meeting disclosed the first comprehensive set of clinical results from Amphivena’s Phase 1 dose escalation study of AMV564 dosed subcutaneously (sc) as monotherapy or in combination with pembrolizumab, including in post checkpoint treatment failures. Poster authors representing Duke University, The Christ Hospital of Cincinnati, OH, MD Anderson Cancer Center, NEXT Oncology, and Moffitt Cancer Center concluded that AMV564 delivered subcutaneously was well tolerated with no dose-limiting toxicities and no maximum tolerated dose reported. Additionally, clinical responses were observed in both monotherapy and combination therapy patients, including durable stable disease, mixed responses, and a RECIST v1.1 complete response (ovarian cancer patient treated with AMV564 monotherapy). Importantly, no cases of CRS were observed at the planned dose expansion doses. According to Patrick Chun, M.D., Amphivena vice president of clinical development, “T cell engagement has proven to be a viable immunotherapeutic strategy in cancer. However, previous technologies have been limited by toxicity (CRS), exposure, and attenuated efficacy. With this data, we are clearly differentiating Amphivena from other companies in the space. Our unique approach uses T cell engagers that target MDSCs, thus attenuating the immunosuppressive milieu in cancer patients, while simultaneously limiting CRS, which has been the primary adverse event of concern with this class of molecules. Based on the clinical safety and pharmacokinetic profiles, along with clinical activity, we believe it is imperative to further explore AMV564 in selected solid tumor indications and alternative dosing regimens, including once weekly dosing.” The poster presents data that AMV564 induced expansion of tumor-specific T-cell clones and clinical responses when administered as a monotherapy and in combination with a checkpoint inhibitor, including in patients who have previously progressed with checkpoint inhibitor treatment. Strong induction of IFNγ was observed with monotherapy and especially in combination, with comparatively low IL6, favorable with respect to both safety and induction of anti-tumor response pathways. The Phase 1 dose escalation study (NCT04128423) enrolled 30 patients (20 monotherapy, 10 combination therapy). The majority of patients received three or more lines of prior therapy (70% of monotherapy patients, 50% of combination therapy patients) including 35% of monotherapy patients and 10% of combination therapy patients who received prior checkpoint-inhibitor therapy. Details of the Presentations: Title: Results of a phase 1 dose-escalation study of AMV564, a novel T-cell engager, alone and in combination with pembrolizumab in patients with relapsed/refractory solid tumors Authors: Niharika B. Mettu, et al. Abstract Number: 2555 The full abstract and poster will be available on the ASCO Annual Meeting 2021 and Amphivena website ( ) as of 9:00AM EDT on Friday, June 4th. About AMV564 AMV564 is a product of Amphivena’s proprietary ReSTORETM (Relieve Suppression of T cells in Oncology and Reinvigorate Effectors) platform of bivalent T-cell engagers. The investigational drug candidate has been shown to relieve immune suppression via targeted depletion of immunosuppressive MDSC and drive T cell activation and polarization to restore anti-cancer immunity. To date, over 80 patients have received AMV564 across three Phase 1 clinical trials for patients with solid tumors, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). About Amphivena Therapeutics, Inc. Amphivena Therapeutics, Inc. is a privately held, clinical-stage, oncology company based in South San Francisco, CA with a mission to restore anti-cancer immunity in patients and to take cancer treatment beyond the limits of immunotherapy. Our proprietary Amphivena ReSTORETM (Relieve Suppression of T cells in Oncology and Reinvigorate Effectors) platform of bivalent T-cell engagers is designed to selectively relieve immune suppression and drive T-cell activation/polarization in patients. The company’s lead therapeutic candidate, AMV564, induces selective T-cell mediated killing of myeloid derived suppressor cells (MDSC), known to be associated with immune suppression and poor outcomes to immunotherapy. In parallel, it drives improved T cell effector function. AMV564-induced immune restoration is optimized by targeting the lymphoid tissues through subcutaneous delivery where immunoregulation occurs. AMV564 has exhibited an excellent clinical safety profile and combinability with checkpoint inhibition and represents a unique opportunity to take bring new treatment options to cancer patients underserved by immunotherapy. Amphivena has raised $88.5 M to date in Series A, B and C venture financings led by NanoDimension, Qiming Venture Partners USA, MPM Capital and funds managed by Tekla Capital Management LLC.

Amphivena Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Amphivena Therapeutics Rank

  • When was Amphivena Therapeutics founded?

    Amphivena Therapeutics was founded in 2012.

  • Where is Amphivena Therapeutics's headquarters?

    Amphivena Therapeutics's headquarters is located at 611 Gateway Blvd, South San Francisco.

  • What is Amphivena Therapeutics's latest funding round?

    Amphivena Therapeutics's latest funding round is Series C.

  • How much did Amphivena Therapeutics raise?

    Amphivena Therapeutics raised a total of $88.5M.

  • Who are the investors of Amphivena Therapeutics?

    Investors of Amphivena Therapeutics include MPM Capital, Merlin Nexus, Nawton Limited, Korys Merieux, Clough Global and 12 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.